Characterized new TRPV(1–3) antagonists could provide interesting molecular tools in the search for new pharmacological agents and for developing a new generation of therapeutics to assess the role of TRPV channels in different cells including the pathobiology of cancer cells. The gene discussed is TRPV1; the disease is cancer.